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Summary Using the rat tumour cell line LY80, a subline of Yoshida sarcoma, the effects of AGM-1470 on the growth of primary tumour and
the incidence of regional lymph node metastasis were evaluated. AGM-1470 (30 mg kg-') was administered subcutaneously or intravenously.
Subcutaneous (s.c.) and intravenous (i.v.) injections were repeated for 8 days and 7 days respectively. Tumour growth of a primary region
tended to be suppressed by AGM-1470. The s.c. tumours after sacrifice were much smaller in the AGM-1470-treated group (s.c. injection)
than in the control groups. However, the growth of metastatic foci in the lymph nodes was prompted markedly by AGM-1470. All six of the
AGM-1470-treated rats had developed swollen axillary lymph nodes and/or brachial lymph nodes on day 19 after tumour implantation (the 7th
day after the lasttreatment) compared with one of six saline-injected rats and three of six vehicle-alone treated rats with swollen axillary lymph
nodes. The weight of lymph nodes after sacrifice in the AGM-1470-treated rats was much heavier than that of the other two groups.
Histological examination showed that in the AGM-1470-treated group, the cortex and the medulla of the axillary lymph nodes were almost
entirely replaced by tumour cells while, in the vehicle alone group, a notable hyperplasia ofthe lymph nodes due to BTcell proliferation tended
to be induced. In the saline group, although a slight hyperplasia of lymph nodes was observed, there were only a fewlymph node metastases.
In the case of i.v. injection of AGM-1470, similar results were obtained. It is thought that LY80 cells spread to regional lymph nodes at a
comparatively early stage by some change or other in which AGM-1470 participated. From the present experiment, it is concluded that
application of AGM-1470 alone to patients should be carried out with great caution.
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It has been reported that AGM-1470, an analogue of fumagillin
isolated from Aspergillus fumigatus, inhibited tumour growth in
mice and rats (Ingber et al, 1990; Yamaoka et al, 1993a; Yanase et
al, 1993) and extended the survival time of animals with some
kinds of tumours (Yamaoka et al, 1993b). Furthermore, in mice
treated with AGM-1470, haematogenous metastasis was strongly
inhibited with regard to both the number and the size of tumour
nodules (Yamaoka et al, 1993b; Tanaka et al, 1995). To date,
however, there have been very few studies on the effects ofAGM-
1470 on lymphogenous metastasis. To improve the chance of
survival, it is important to inhibit not only haematogenous metas-
tasis but also lymphogenous metastasis, because metastases to the
regional lymph nodes occur very frequently in cancer patients.
The purpose of the present study was to evaluate the effects of
AGM-1470 on both the growth of primary s.c. tumours and the
incidence of regional lymph node metastasis. Using a model of
lymph node metastasis, we used the LY80 tumour cell line system,
in which tumour cells spontaneously and uniformly metastasized
from the primary s.c. site to axillary and/or brachial lymph nodes
after s.c. tumour transplantation. We found that regional lymph
node metastases became prominent after AGM-1470 injection.
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MATERIALS AND METHODS
Rats and tumour
Male Donryu rats (Crj-Donryu; Nippon Charles-River, Yokohama,
Japan), weighing 180-220 g each at inoculation, were used. They
were housed in plastic cages in an air-conditioned room at a
temperature of 25 ± 1PC, and food and water were available ad
libitum. The tumour used was LY80 (established in 1966 by Dr H
Satoh), a subline of Yoshida sarcoma, which has been maintained
in our laboratory by successive i.p. transplantation. Cells (2 x 106)
in 0.1 ml were injected s.c. into the back of each rat. LY80 has a
99% take rate when 2 x 106 cells are implanted subcutaneously.
The incidence ofaxillary and/or brachial lymph node metastases is
usually about 30% at 3 weeks and 90% at 4 weeks after tumour
cell implantation. However, the primary tumour of LY80 cells
scarcely develops haematogenous metastases into other organs.
The cells are insensitive to many of the anti-cancer drugs that are
used clinically. The metastasis of the cells to the regional lymph
node is not enhanced by anti-cancer drugs.
The volume (V) of s.c. tumour was calculated using a standard
formula:
V=(nt/6)xdl xd2xd3
where dl, d2 and d3 are the long axis, the short axis and the height
of the tumour nodule respectively. Experiments were performed
according to a protocol approved by the Animal Experiment
Committee of our Institute.
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Figure 1 The effects of s.c. injection of AGM-1470 on the growth of s.c.
LY80 tumour. The therapy was started on day 5 after the tumour cell
implantation (2 x 106). AGM-1470 (30 mg kg-1) was administered
subcutaneously once a day for 8 days (arrows). Each point represents the
mean ± s.d. 0, AGM-1 470-treated group (n = 6); *, vehicle-alone group
(n = 6); 0, saline group (n = 6)
Table 1 The weights of the lymph nodes in the AGM-1470-treated group
(subcutaneous injection), vehicle-alone group and saline group
Lymph nodes (g)
No. Axillary Brachial
Left Right Left Right
AGM-1470-treated group
1 <0.02 1.67 < 0.02 0.41
2 0.04 0.50 0.03 1.03
3 0.03 0.88 < 0.02 0.85
4 0.09 0.03 < 0.02 < 0.02
5 0.03 0.52 0.15 0.25
6 0.26 0.19 0.80 0.04
Vehicle-alone group
1 0.05 0.02 < 0.02 < 0.02
2 1.53 0.05 0.97 < 0.02
3 <0.02 <0.02 <0.02 <0.02
4 0.02 0.03 < 0.02 < 0.02
5 0.31 0.03 1.00 <0.02
6 0.03 1.06 0.02 <0.02
Saline group
1 0.02 < 0.02 < 0.02 0.02
2 0.19 0.02 1.49 < 0.02
3 0.03 0.03 < 0.02 < 0.02
4 x 0.02 <0.02 <0.02 <0.02
5 0.03 0.02 < 0.02 < 0.02
6 0.04 0.02 < 0.02 < 0.02
Chemicals
AGM-1470 (in crystalline powder) for animal treatment and the
clinical formulation of the reagent were kindly provided by
Takeda Chemical Industries, Osaka, Japan. The AGM-1470
powder was dissolved in a vehicle composed of 1% ethanol plus
5% gum arabic in 0.9% sodium chloride solution, resulting in a
final concentration of 3 mg ml'. The clinical formulation of
AGM-1470 was dissolved in 0.9% sodium chloride solution,
resulting in a final concentration of50 mg ml',just before use.
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Figure 2 The effect of i.v. injection of AGM-1470 on the growth of s.c. LY80
tumour. The therapy was started on day 3 after the tumour cell implantation
(2 x 106). AGM-1470 (30 mg kg-') was administered into the tail vein once a
day for 7 days (arrows). Each point represents the mean + s.d. 0, AGM-
1470-treated group (n = 4); 0, saline group (n = 5)
Therapy with AGM-1470
Therapy with AGM-1470 was performed two times using two
different injection routes, i.e. via subcutis and vein. The rats ofthe
first therapy (a) were divided into three groups, i.e. a group in
which AGM-1470 (30 mg kg-') was administered subcutaneously
(AGM-1470-treated group, six rats), a group in which vehicle
alone was administered (vehicle-alone group, six rats) and a group
in which 0.9% sodium chloride solution was administered (saline
group, six rats). The site of s.c. administration was the caudal
portion approximately 3 cm distant from the s.c. tumour. The
therapy was started on day 5 after the tumour cell implantation
(2 x 106) and was continued for 8 days.
The second therapy (b) was started on day 3 after tumour cell
implantation (2 x 106). The clinical formulation of AGM-1470
(30 mg kg-') was administered intothe tail vein at aconstantrate of
0.003 ml s-I using a microinfusion pump (Compact syringe pump;
Harvard Apparatus, Mills, MA, USA) under anaesthesia with light
ether sedation every day for 7 days. Control animals were given
0.9% sodium chloride solution alone by the same method.
Evaluation of therapeutic effect
The therapeutic efficacy andtoxicity due to AGM-1470 were eval-
uated by measuring the change of the tumour size and body
weight. Tumour size and body weight were measured every day.
On day 8 (a) and day 12 (b) after the last treatment, all the rats
were killed with deep ether anaesthesia for examination; the
weights of enlarged lymph nodes were recorded. After measure-
ments of lymph node weight, for routine histology, the lymph
nodes were fixed in 10% formalin and processed and embedded in
paraffin for haematoxylin and eosin staining.
Statistical analysis
Results concerning tumour size and body weight of rats were
expressed as means ± s.d. Differences in data were analysed using
Student's t-test. Differences in the incidence of lymph node meta-
stasis in the AGM-1470-treated group, the vehicle-alone group
and the saline group were statistically analysed by Fisher's direct
probability test. P < 0.05 was considered to be significant.
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Figure 3 The macroscopical observation of swollen axillary and brachial
lymph nodes in the AGM-1470-treated group (A) and the saline group (B)
after sacrifice. Bar = 15 mm
RESULTS
Effects of AGM-1470 on tumour size and lymph node
metastasis
The growth of s.c. LY80 tumour was suppressed significantly by
subcutaneous administration of AGM-1470 (P < 0.01) (Figure 1).
Conversely, lymph node metastases were strongly prompted by
AGM-1470. All six of the AGM-1470-treated rats had developed
swollen axillary lymph nodes and/or brachial lymph nodes on day
19 after tumour implantation (the 7th day after the last treatment)
compared with one of six control rats and three of six vehicle-
alone rats with swollen axillary lymph nodes. The effects of s.c.
injection ofAGM-1470 on the weight of lymph nodes in Donryu
rats are summarized in Table 1. The weight oflymph nodes in the
AGM-1470-treated group after sacrifice was greater than that in
the other two groups.
Figure 2 shows the effect ofintravenous injection ofAGM-1470
on tumour growth. The activity of AGM-1470 upon i.v. injection
was weaker than that following s.c. injection. There was no signif-
icant difference between the AGM-1470-treated group and the
control group (P = 0.262). The macroscopical observation of
lymph nodes in the control group and the AGM-1470-treated
group after sacrifice is shown in Figure 3. It is clear that AGM-
1470 prompted lymph node metastases. These results were analo-
gous to the case of s.c. injection ofAGM-1470.
Histological examination
The results of the histological examination of the lymph node
metastases in the AGM-1470-treated group (s.c. injection), the
vehicle-alone group and the saline group are summarized in Table
2. Lymph node metastases were significantly enhanced in the
AGM-1470-treated group compared with the other two groups
(P < 0.001). In the AGM-1470-treated group, the cortex and the
medulla of the axillary lymph nodes are almost entirely replaced
by tumour cells (Figure 4A and B) and tumour vessels are also
recruited abundantly (Figure 4B). The tumours in the lymph nodes
after the application of AGM-1470 have almost the same vessel
Table 2 The histological examination of the lymph nodes in the AGM-1470-
treated group (subcutaneous injection), vehicle-alone group and saline group
Lymph nodes metastasis
No. Axillary Brachial
Left Right Left Right
AGM-1470-treated group
1 - ++ - ++
2 + ++ + ++
3 ++ ++ - ++
4 ++ _ _
5 + ++ ++ ++
6 ++ ++ ++ ++
Vehicle-alone group
1 _ _ _
2 ++ + _
3 - _ -
4 - _ _
5 4+ _ ++ _
6 - ++ -
Saline group
1 _ _ _
2 ++ _ ++ -
3 ++ _ _
4 - _ _
5 - _ _
6 - _ _
-, No metastasis; +, partial replacement of lymph node by tumour cells; ++,
complete replacement of lymph node by tumour cells. AGM-1470-treated
group vs vehicle-alone group, P< 0.001. AGM-1470-treated group vs saline
group, P< 0.001. Vehicle-alone group vs saline group, not significant.
density as that of untreated control s.c. tumours. In the vehicle-
alone group, a notable hyperplasia of the lymph nodes due to BT
cell proliferation was observed (Figure 4C and D). In the saline
group, although a slight hyperplasia of the lymph nodes was
observed (Figure 4E and F), there were only a few lymph node
matastases. The results of i.v. injection of AGM-1470 were also
similar to those of s.c. injection.
Effects of AGM-1470 on body weight
The effect ofAGM-1470 on the body weight ofthe rat is shown in
Figure 5. Figure 5A shows serial changes of body weight during
and after s.c. injection of AGM-1470, and Figure 5B shows the
results following i.v. injection. Body weightloss was largerthrough
i.v. injection, whereas there was no loss of body weight following
s.c. administration but instead a slowerrate ofweight gain.
DISCUSSION
Our results showed that, although AGM-1470 tended to inhibit the
growth of primary tumour of LY80 cells in Donryu rats, it
enhanced lymph node metastasis. Many studies regarding AGM-
1470 have been reported. However, there are very few papers indi-
cating the effects of AGM-1470 on the incidence and growth of
lymph node metastasis. One reason may be the fact that there are
very few tumour cell lines that metastasize spontaneously to
regional lymph nodes. The LY80 cell line system used in the
present experiment is suitable as a model of lymph node meta-
stasis; this is because LY80 cells metastasize spontaneously and
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Figure 4 Photomicrographs of the axillary lymph nodes from the AGM-1470-treated group (A and B), the vehicle alone group (C and D) and the saline group
(E and F). A, C and E x 40; B, D and F x 400. In the AGM-1470-treated group, the axillary lymph node is completely replaced by tumour cells. In the vehicle-
alone and the saline group, a hyperplasia of the lymph nodes is notable
uniformly from the primary s.c. site to axillary and/or brachial
lymph nodes in almost all rats in which they develop secondary
tumours approximately 3-4 weeks after s.c. tumour cell transplan-
tation. However, it was found that, on histological examination, no
metastases were observed in the lymph nodes of many rats within
3 weeks after tumour transplantation (data not shown). Thus, the
finding that, in the AGM-1470-treated group, the axillary and/or
the brachial lymph nodes of all rats became palpable within 2-3
weeks suggests that LY80 cells had reached regional lymph nodes
at a comparatively early stage by some change or other in which
AGM-1470 participated.
On the other hand, as described by many other researchers,
tumour growth in the primary region was suppressed by s.c. injec-
tion ofAGM-1470. The finding that the suppression by s.c. injec-
tion ofAGM-1470 was more remarkable than that by i.v. injection
suggests that the duration of the concentration of AGM-1470 in
blood plasma was responsible. Many of the in vivo effects due to
AGM-1470 are considered to be caused by antiangiogenic
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Figure 5 Changes in body weight of tumour-bearing rats during and after
AGM-1 470 treatment. Each point represents the mean ± s.d. (A) s.c. injection
of AGM-1 470: v, AGM-1470-treated group (n = 6);E, vehicle-alone group
(n = 6); 0, saline group (n = 6). (B) i.v. injection of AGM-1e470:, AGM-1470-
treated group (n = 4); 0, saline group (n = 5). Arrows show AGM-1 470
(30 mg kg-') injection
activity; that is, in an in vitro system, AGM-1470 completely
inhibited both basic fibroblast growth factor (bFGF)-induced cell
growth and vascular endothelial growth factor (VEGF)-induced
cell growth in capillary endothelial cells (Toi et al, 1994) and, in a
rat blood vessel organ culture assay, it was found to selectively
inhibit the capillary-like tube formation of endothelial cells
(Kusaka et al, 1991).
Kurebayashi et al (1994) reported that s.c. injection of AGM-
1470 obviously inhibited the tumour growth and lymph node
metastasis of MKL-4 cells in nude mice. The MKL-4 is a cell line
that was artificially produced byeukaryotic vector transfection and
exhibits spontaneous metastases into lymph nodes, lungs, kidneys
and liver. Using a model of rats implanted with the fibrosarcoma
cell line AS653HM in the footpad, Futami et al (1994) reported
similar results.
On the other hand, McLeskey et al (1996) have reported that no
effect of AGM-1470 was seen on lymph node metastases using a
transfected model in immunocompromised mice. Antoine et al
(1996) have reported that AGM-1470 promotes the hyperplasia of
regional lymph nodes due to TB cell proliferation. Their results
suggest that AGM-1470 might have an effect on the immune
system. In addition, Pollard (1996) has recently reported that one
of the antiangiogenic agents, thalidomide, promotes lymph node
metastasis of rat prostate adenocarcinoma. Our present results
have many points of similarity to Pollard's results. He speculates
that the increased incidence of metastases due to thalidomide
might be in part attributed to an immunosuppressive action of
thalidomide. AGM-1470 might have a similar influence on the
immune system of the LY80 tumour-bearing Donryu rats. Thus,
further studies are needed to clarify why the incidence and growth
of metastasized regional lymph node in rats implanted with LY80
are increased by AGM-1470 and why the tumour vessel formation
in lymph nodes is not suppressed by AGM-1470.
In conclusion, the results in the present study showed that
AGM-1470 promotes lymph node metastasis of LY80 cells. This
fact suggests that there is the possibility that, in some cancer
patients, lymph node metastases might be enhanced by AGM-
1470 in the same way. Accordingly, application ofthis agent alone
to patients should be carried out with great caution.
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